Journal Reviews

Performance status may alter outcomes in those treated with abiraterone

1 May 2015 | | Urologic Oncology | Abiraterone acetate, Castration-resistant prostate cancer, ECOG, Performance status, Prostate cancer

The drug therapies available for those with metastatic castrate-resistant prostate cancer have increased over the past few years. Abiraterone, a CYP17 inhibitor, has been proven effective in phase three trials, however those with poor performance status were largely under-represented in...